MDACC Study No:2008-0363 ( NCT No: NCT00857389)
Title:Thiotepa-Clofarabine-Busulfan with Allogeneic and Haploidentical Stem Cell Transplant for High Risk Malignancies
Principal Investigator:Laura L. Worth
Treatment Agent:Busulfan; Clofarabine; Cyclophosphamide; MESNA; Thiotepa; Total Body Irradiation
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if thiotepa, busulfan, and
clofarabine, when given before an allogeneic (bone marrow , blood, or cord
blood cells) or halpoidentical (bone marrow) stem cell transplantation can help
to control cancers of the bone marrow and lymph node system. The safety of this
treatment will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Blood And Marrow Transplantation; Leukemia; Lymphoma; Pediatrics
Phase of Study:Phase II
Treatment Agents:Busulfan
Total Body Irradiation
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Approximately 30 days
Supported By:N/A
Return Visit:Upon discharge patients may be required to return daily until Day +100, then 3
months, 6 months, and 12 months post-transplant or at other time points if
clinically indicated.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Laura L. Worth
For Clinical Trial Enrollment:713-792-6620
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults